Article thumbnail

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

By Yung-Sung Yeh, Hsiang-Lin Tsai, Ching-Wen Huang, Jui-Ho Wang, Yi-Wen Lin, Hsiu-Chih Tang, Yung-Chuan Sung, Chang-Chieh Wu, Chien-Yu Lu and Jaw-Yuan Wang
Publisher: Springer Nature
Year: 2016
DOI identifier: 10.1186/s13063-016-1153-3
OAI identifier:

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.